Bezafibrate-d4 structure
|
Common Name | Bezafibrate-d4 | ||
---|---|---|---|---|
CAS Number | 1189452-53-6 | Molecular Weight | 365.84 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | 572.1±45.0 °C at 760 mmHg | |
Molecular Formula | C19H16D4ClNO4 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 299.8±28.7 °C |
Use of Bezafibrate-d4Bezafibrate-d4 is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent. |
Name | Bezafibrate |
---|---|
Synonym | More Synonyms |
Description | Bezafibrate-d4 is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent. |
---|---|
Related Catalog | |
In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 572.1±45.0 °C at 760 mmHg |
Molecular Formula | C19H16D4ClNO4 |
Molecular Weight | 365.84 |
Flash Point | 299.8±28.7 °C |
Exact Mass | 361.108093 |
LogP | 3.46 |
Vapour Pressure | 0.0±1.7 mmHg at 25°C |
Index of Refraction | 1.583 |
3968 |
Bezalip |
MFCD00078970 |
a-[4-(4-Chlorobenzoylaminoethyl)phenoxy]isobutyric Acid |
Bezafibrate |
2-[p-[2-(p-Chlorobenzamido)ethyl]phenoxy]-2-methylpropionic Acid |
bezafibratum [INN_la] |
2-[4-[2-[(4-Chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic Acid |
Y9449Q51XH |
Propanoic acid, 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl- |
2-(4-{2-[(4-Chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid |
EINECS 255-567-9 |